# Comparing Semaglutide, Tirzepatide & Retatrutide — NextGen Peptides

> Side-by-side comparison of the three incretin-class research peptides: receptor targets, trial-measured weight-loss effect sizes, evidence base, administration, regulatory status, and key cautions.

One table, three compounds, the effect sizes as the trials measured them.

## The short version

These three compounds form a pharmacological progression: each adds a receptor target and, in trials to date, each produces larger weight-loss numbers. The table below places the key dimensions side by side. Two are FDA-approved medicines. One is investigational. The trial designs are not identical — a Phase 2 result (retatrutide) is not directly comparable to a Phase 3 result (semaglutide, tirzepatide) — and that asymmetry is flagged in the table and the commentary below.

## Side-by-side comparison

| Dimension | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Peptide class | GLP-1 receptor agonist | GIP/GLP-1 dual receptor agonist | GIP/GLP-1/glucagon triple receptor agonist |
| Most studied in | Adults with type 2 diabetes, obesity (no diabetes), established CVD | Adults with type 2 diabetes, obesity (no diabetes) | Adults with obesity (no diabetes), type 2 diabetes, MASLD |
| Evidence base | Phase 3 (multiple large RCTs; Phase 3b head-to-head) | Phase 3 (multiple large RCTs; Phase 3b head-to-head) | Phase 2 RCTs only; Phase 3 (TRIUMPH) ongoing |
| Best weight-loss result | -14.9% at 68 wk (STEP 1, sema 2.4 mg, n=1,961) [4] | -20.9% at 72 wk (SURMOUNT-1, tirz 15 mg, n=2,539) [10] | -24.2% at 48 wk (Phase 2, reta 12 mg, n=338) [15] |
| Administration studied | Once-weekly subcutaneous injection or once-daily oral tablet | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (Phase 2/3) |
| Regulatory status | FDA-approved: type 2 diabetes, chronic weight management, CV risk reduction, MASH (2025) | FDA-approved: type 2 diabetes, chronic weight management, obstructive sleep apnea | Investigational; no FDA or regulatory approval as of mid-2026 |
| Key caution | GI tolerability; gallbladder disease; lean-mass loss; retinopathy with rapid glycemic correction [5][7] | GI tolerability; gallbladder disease (RR 1.97 vs controls) [9]; lean-mass loss; heart rate elevation less prominent than retatrutide | Heart-rate increase (GCGR-mediated, ~5-7 bpm, dose-dependent) [15]; unapproved — no manufacturing oversight outside trials |

## Weight loss: reading the numbers correctly

The progression from -14.9% (semaglutide) to -20.9% (tirzepatide) to -24.2% (retatrutide) looks linear, but the studies differ in ways that prevent a clean comparison.

The semaglutide STEP 1 trial ran 68 weeks; the tirzepatide SURMOUNT-1 trial ran 72 weeks; the retatrutide Phase 2 ran 48 weeks. Longer trials generally show more weight loss as the plateau sets in later — which means the retatrutide -24.2% at 48 weeks may actually understate what its 72-week figure would be, based on the trial's trajectory. Phase 3 data will clarify this.

The only direct head-to-head published as of mid-2026 is SURMOUNT-5, which compared semaglutide and tirzepatide under matched conditions: the difference at 72 weeks was -20.2% versus -13.7%, approximately 6.5 percentage points in favor of tirzepatide (P<0.001) [1]. No equivalent head-to-head involving retatrutide has reported.

For cardiovascular outcomes, only semaglutide has completed large dedicated outcome trials (SELECT, SUSTAIN-6, FLOW). Tirzepatide's cardiovascular-outcomes program is ongoing. Retatrutide's is also ongoing; no outcome data exist.

## Regulatory status: why it matters

Semaglutide and tirzepatide are FDA-approved prescription medicines. Their approved formulations have undergone full Phase 3 development, manufacturing quality review, and post-market pharmacovigilance. The evidence base reported on this desk reflects that process.

Retatrutide has not completed that process. Its Phase 2 data are real and peer-reviewed, but Phase 3 programs (the TRIUMPH series) are ongoing and have not reported. No regulatory agency has reviewed the compound for approval. Gray-market research-channel formulations — sold as retatrutide outside clinical trials — carry documented risks from the absence of pharmaceutical-grade manufacturing, verified identity, and sterility testing [12].

This difference is material when interpreting the numbers: a Phase 2 trial result is not the same as an approved label.

## Key shared cautions across the class

All three compounds share the incretin class profile:

- **GI tolerability** is the dominant adverse-effect category across all three. Nausea, vomiting, constipation, and diarrhea are dose-related and most prominent during escalation. They are generally mild-to-moderate and transient, but drive the majority of discontinuations in trials [5][9][15].
- **Lean-mass loss** alongside fat mass is documented across the class. Body-composition substudies consistently show 25-30% of lost weight is lean tissue.
- **Weight regain after discontinuation** is documented for semaglutide and tirzepatide; by analogy with the class, retatrutide is expected to show the same pattern. This frames all three as chronic rather than short-course interventions.
- **Gallbladder and biliary disease** is significantly increased for both semaglutide [5] and tirzepatide [9]; rapid weight loss is the proposed mechanism.
- **Thyroid C-cell tumor concern** carries a class boxed warning for GLP-1 receptor agonists; this applies to all three.

---

A literature digest of peer-reviewed incretin research — effect sizes reported as published, not as clinical guidance.